Toward an effective strategy in glioblastoma treatment. Part II: RNA interference as a promising way to sensitize glioblastomas to temozolomide.


Autoria(s): Messaoudi, Khaled; Clavreul, Anne; Lagarce, Frédéric
Contribuinte(s)

Micro et nanomédecines biomimétiques (MINT) ; Université d'Angers (UA) - Institut National de la Santé et de la Recherche Médicale (INSERM)

CHU Angers (CHU Angers) ; CHU Angers

Data(s)

2015

Resumo

International audience

<p>RNA interference (RNAi) is a strategy of gene regulation that has opened up many opportunities for the treatment of cancers, especially glioblastoma multiforme (GBM). This strategy reduced the expression of many proteins involved in the resistance of these tumors to anticancer drugs, particularly to temozolomide (TMZ). A significant research effort has gone into RNAi delivery and target selection for clinical application of this new discovery in the treatment of GBMs. However, some limitations must be resolved to enhance the safety of RNAi-based therapeutics and to reduce their immune response. In this review, the mechanism of RNAi will be described. Moreover, the opportunities offered by RNAi strategy to reverse the phenotype of these tumor cells as well as prospects and challenges ahead in the RNAi-based therapy will be discussed.</p>

Identificador

hal-01392444

https://hal.archives-ouvertes.fr/hal-01392444

DOI : 10.1016/j.drudis.2015.02.014

OKINA : ua10639

Idioma(s)

en

Publicador

HAL CCSD

Relação

info:eu-repo/semantics/altIdentifier/doi/10.1016/j.drudis.2015.02.014

Fonte

ISSN: 1878-5832

Drug Discovery Today

https://hal.archives-ouvertes.fr/hal-01392444

Drug Discovery Today, 2015, 20, pp.772-9. <10.1016/j.drudis.2015.02.014>

Palavras-Chave #[SDV] Life Sciences [q-bio]
Tipo

info:eu-repo/semantics/article

Journal articles